Invasive procedures for body sculpting, such as liposuction and abdominoplasty surgeries, provide pronounced results but are associated with the risk of severe side effects, high financial costs, and prolonged recovery time.1–4 For nonobese individuals and those seeking lower risk, more economical, and localized fat reduction, noninvasive and minimally invasive cosmetic techniques have become popular.5 Nonsurgical procedures for localized subcutaneous fat reduction, such as low-level laser therapy, laser lipolysis (using 1060-and 1064-nm lasers), cryolipolysis, radio frequency, and high-intensity focused ultrasound, lead to shorter downtime. However, patient satisfaction levels and the severity of adverse effects vary across modalities, ranging from mild symptoms like transient erythema, pain, and bruising to more severe complications, including dermal injury, subcutaneous nodules, severe frostbite, asymmetry, and postcryolipolysis paradoxical adipose hyperplasia.5–10 Furthermore, the fat reduction efficacy of each of these noninvasive treatments depends on the consistent and optimal use of the respective high-cost devices.11
There is considerable interest and potential for the use of injection lipolysis for targeted and localized subcutaneous fat reduction. ATX-101 (deoxycholic acid injection), currently the only FDA-approved minimally invasive injectable treatment for fat reduction, has shown efficacy in reducing submental fat,12–14 with sustained results up to 3 years in most patients,15 but its associated adverse effects include skin necrosis, ulceration, neuropraxia of the marginal mandibular nerve, and infections.16 The use of ATX-101 for targeted fat reduction over larger body areas remains under-explored.17
CBL-514 (Caliway Biopharmaceuticals, New Taipei City, Taiwan) is a small-molecule injection lipolysis agent that promotes adipocyte apoptosis and targeted subcutaneous fat reduction in nonclinical studies without causing any skin necrosis, ulceration, nerve injury, and systemic side effects. (Caliway Biopharmaceuticals, unpublished confidential reports).18 In a proof-of-concept Phase 2a study (ClinicalTrials.gov: NCT04698642), single doses of CBL-514 showed a favorable and acceptable safety profile as well as efficacy in reducing subcutaneous abdominal fat at multiple dose levels.17 Here, we report results from a randomized, single-blind, placebo-controlled, parallel-group Phase 2 study to further assess CBL-514 efficacy and safety for abdominal fat reduction (Clinical trial registration no.: NCT04897412; https://clinicaltrials.gov/study/NCT04897412).
